Technology

Zoghbi, Bird Honored for Work on Epigenetics in Neurological Diseases

Published

4 hours ago

September 2, 2026

HOUSTON, Sept. 2, 2026 /PRNewswire/ — Dr. Huda Zoghbi, founding director of the Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s and Distinguished Service Professor and Howard Hughes Medical Institute Investigator at Baylor College of Medicine, along with her long-time collaborator Dr. Adrian Bird, professor at the University of Edinburgh, will be awarded the prestigious 2026 Louisa Gross Horwitz Prize from Columbia University for their pioneering work on epigenetic regulation in the nervous system and its role in human neurological disease, particularly Rett syndrome.

Primarily affecting girls, Rett syndrome is a severe neurodevelopmental disorder that impacts nearly every aspect of life, including the ability to speak, walk, control hand movements, eat, breathe, think, and control seizures. Before the discoveries of Zoghbi and Bird, the disorder was poorly understood and considered untreatable. Today, with lifelong support, individuals with Rett syndrome can live well into adulthood.

Zoghbi discovered in 1999 that mutations in MeCP2 cause Rett syndrome, establishing the first direct link between epigenetics and a severe neurological disorder and enabling early detection of the disease by genetic testing. She also showed that MeCP2 levels must be precisely maintained for neurons to function normally. Too little MeCP2 causes Rett syndrome, while doubling MeCP2 levels causes neurological deficits. Later work revealed that MeCP2 mutations also contribute to a range of other neurological conditions, from autism to juvenile-onset schizophrenia.

Bird uncovered key principles of epigenetic regulation, a chemical process that turns genes on and off without altering their underlying code. In the 1980s, he discovered CpG islands, specialized DNA clusters present near the start of genes. A decade later, his lab identified MeCP2, a protein that scans for chemical tags called methyl groups attached to these clusters and, upon finding them, switches the nearby gene off, acting like a molecular “off switch” for gene activity in neurons and throughout the body.

Though Rett syndrome was thought to cause permanent brain damage, Zoghbi and Bird showed that it could be reversible. Bird’s group engineered the first mouse model of Rett syndrome and, in 2007, showed that reactivating MeCP2 in these mice dramatically improved neurological symptoms. Zoghbi’s team showed that the effects of abnormal levels of functional MeCP2 can be reversed in mice by oligonucleotide therapy. Based on this work, a new generation of gene replacement (TSHA-102 and NGN-401) and RNA-regulating (ION 440) drugs, are now advancing through clinical development.

“Together, these two scientists have forged a remarkable path from fundamental discovery to therapeutic possibility, exemplifying the highest ideals of biomedical research,” said Laura Landweber, chair of Columbia’s Horwitz Prize committee.

“Their collective work has transformed our understanding of the molecular basis for a significant human disease and brought renewed hope to patients and families affected by devastating neurological disorders,” added Henry Colecraft, a member of the prize committee.

Zoghbi and Bird are the 122nd and 123rd winners of the Horwitz Prize, which is awarded annually by Columbia University for groundbreaking work in medical science. Of the 121 previous Horwitz Prize winners, 55 have gone on to also receive Nobel Prizes.

About Texas Children’s
Texas Children’s, a nonprofit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children’s hospital in Texas and among the top in the nation, Texas Children’s has garnered widespread recognition for its expertise and breakthroughs in pediatric and women’s health. The system includes the Texas Children’s Duncan NRI; the Feigin Tower for pediatric research; Texas Children’s Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children’s Hospital West Campus, a community hospital in suburban West Houston; Texas Children’s Hospital The Woodlands, the first hospital devoted to children’s care for communities north of Houston and Texas Children’s Hospital North Austin, the new state-of-the-art facility providing world-class pediatric and maternal care to Austin families. The organization also created Texas Children’s Health Plan, the nation’s first HMO focused on children; Texas Children’s Pediatrics, the largest pediatric primary care network in the country; Texas Children’s Urgent Care clinics that specialize in after-hours care tailored specifically for children; and a global health program that is channeling care to children and women all over the world. Texas Children’s Hospital is affiliated with Baylor College of Medicine. For more information, visit www.texaschildrens.org.

Media Contact:
Texas Children’s Public Affairs
PublicAffairs@texaschildrens.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/zoghbi-bird-honored-for-work-on-epigenetics-in-neurological-diseases-302867870.html

SOURCE Texas Children’s Hospital

Technology

Lemonade Brings Car Insurance and Autonomous Car to Missouri

Published

38 minutes ago

September 2, 2026

Lemonade Car with Tesla FSD (Supervised) pricing available now

NEW YORK, Sept. 2, 2026 /PRNewswire/ — Lemonade (NYSE: LMND), the tech-first insurance company, today announced the launch of Lemonade Car in Missouri, along with Lemonade Autonomous Car, giving Missouri Tesla drivers 50% off every mile driven using Full Self-Driving (Supervised) on day one.

“Missouri drivers are getting Lemonade Car and Lemonade Autonomous Car at the same time, which is a first for us,” said Shai Wininger, President and Co-Founder of Lemonade. “Tesla’s safe FSD (Supervised) tech reduces the chances of getting into an accident. Our intelligent pricing models see this in the data and can pass real savings, with high precision, on to Tesla customers, right from the start.”

Missouri drivers can now get a quote in seconds through the Lemonade app or at lemonade.com/car and Tesla owners can enroll in Autonomous Car pricing at tesla.lemonade.com/fsd.

Further savings are available when bundled with Lemonade Renters, Pet, or Home insurance.

About Lemonade

Lemonade’s mission is to become the most loved insurance company in the world. As a customer-centric tech company, we created an insurance experience across Renters, Home, Pet, Car, and Life that is smart, instant, and delightful. Our team of 1,200+ Lemonade Makers makes it possible for over 3M customers throughout the US, UK and Europe to get coverage instantly, with nearly half of claims paid in a matter of seconds. Powered by AI and social impact, Lemonade is a purpose-built, technology-first insurance carrier. A Certified B-Corp, our commitment to social impact is embedded in every aspect of the company, and our Giveback program, which donates a percentage of leftover premiums to nonprofits selected by our community, has donated over $10M to organizations in need.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lemonade-brings-car-insurance-and-autonomous-car-to-missouri-302868053.html

SOURCE Lemonade, Inc.

Technology

MD Integrations Partners With LegitScript, Offering Telehealth Brands Expedited Path to Compliant Launch

Published

38 minutes ago

September 2, 2026

MD Integrations is partnering with LegitScript as an Enterprise Certification Partner, offering expedited certification packages to virtual care and telehealth brands seeking compliance as a competitive advantage.

NEW YORK, Sept. 2, 2026 /PRNewswire/ — MD Integrations, the only unified telehealth platform built on a nationwide, doctor-only network, announced a partnership with LegitScript. The partnership embeds LegitScript certification directly into MD Integrations’ onboarding workflow, giving telehealth and virtual care brands a single, streamlined path to compliance, with Legitscript application reviews beginning in as little as two business days.

“In digital healthcare, every week of delay and non-compliance is a missed opportunity to serve patients and grow your brand compliantly in the virtual care ecosystem,” said Dr. Marc Serota, Founder and CEO of MD Integrations. “By combining LegitScript’s compliance expertise with our leading provider-led infrastructure, we are excited to deliver the most comprehensive and compliant centralized digital health solution for telehealth and virtual care companies.”

“Telehealth founders do not have the luxury of choosing between speed-to-market and compliance. This partnership means MD Integrations’ brand partners get both from day one. When certification is proactively built into onboarding, brands launch faster and pursue advertising with confidence on platforms like Google and Meta from the start.” Angela Salter, VP of Enterprise Certification Sales and Strategic Partnerships of LegitScript.

An Embedded End-to-End Certification Path

As an Enterprise Certification Partner, MD Integrations now offers brand partners:

Expedited review: With MD Integrations, applications are expedited through LegitScript and can be picked up in as little as two days, while standard LegitScript review wait times can be 4-6 weeks before work begins. This will help speed up brand launches, compliant digital advertising campaigns, and patient acquisition funnels.Dedicated support through MD Integrations: Pairing LegitScript’s certification with MD Integrations’ clinical infrastructure brings a comprehensive solution for compliance-as-a-service, driven by the combination of LegitScript certifications through MD Integrations and its physician-only network and enterprise-grade infrastructure.End-to-end coverage: Many infrastructure providers recommend certification but don’t manage, fast-track, or integrate it into their onboarding process.

By combining the industry’s most integrated, physician-only clinical infrastructure with expedited access to LegitScript certification, MD Integrations removes a critical growth bottleneck for telehealth and virtual care brands, delivering the rapid and compliant turnaround, reducing time-to-launch, and accelerating brands’ path to revenue and scale.

Seamless Integration

As an Enterprise Certification Partner, MD Integrations embeds LegitScript certification directly into its onboarding process, enabling a connected workflow for LegitScript certification. Through MD Integrations, brands can seamlessly apply for LegitScript certification and have questions addressed through a centralized source and streamline input.

End-to-End Support, From Application Through Renewal: MD Integrations provides dedicated support across the full certification lifecycle:Dedicated LegitScript support: A dedicated LegitScript account manager for MD Integrations helps guide brand partners through the certification application and answers questions as they arise.Renewal management: Available to brands working with MD Integrations to ensure compliance is maintained without disaggregating relationships or outsourcing to other providers.

Clinician-Led, Compliance-First by Design

MD Integrations’ approach to certification is anchored in the same physician-led model that underpins its clinical network. Because the MD Integrations platform is built and operated with real-world clinical and regulatory expertise from board-certified MDs and DOs, compliance is treated as a foundational part of the infrastructure rather than a separate function layered on top. That same expertise now extends directly into how brand partners navigate LegitScript certification.

About MD Integrations

MD Integrations is a clinical infrastructure company powering a physician-only network of board-certified MDs and DOs across all 50 US states, DC, Puerto Rico, Guam and Canada.
MD Integrations partners with more than 200 healthcare brands across specialties including weight management, longevity, women’s health, and dermatology, giving founders and operators the clinical backbone to launch and scale compliant telehealth services without building physician networks or clinical infrastructure from scratch. Learn more about our partnership and MD Integrations at www.mdintegrations.com.

Media Contact: press@mdintegrations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/md-integrations-partners-with-legitscript-offering-telehealth-brands-expedited-path-to-compliant-launch-302868059.html

SOURCE MD Integrations

Technology

Telit Cinterion to Onshore its Trusted Manufacturing to the United States

Published

38 minutes ago

September 2, 2026

The largest western IoT player to onshore manufacturing of cellular modules and products in the U.S. with production starting in October 2026

Pennsylvania facility: New manufacturing facility in the heart of the nation’s largest defense industrial complex establishes domestic production capacity to support critical infrastructure customers, advances America’s technology manufacturing base, and creates local jobs.Location is key: Pennsylvania supports Telit Cinterion’s position as the leading IoT module vendor to critical national infrastructure, defense and mission critical applications globally.First in industry: Telit Cinterion is bringing its pioneering trusted and secure technology, developed over 30 years in the U.S. and allied nations, to be manufactured domestically.

BOCA RATON, Fla., Sept. 2, 2026 /PRNewswire/ — Telit Cinterion, a global Internet of Things (IoT) enabler, today announced that it is expanding its global manufacturing apparatus by adding operations in the United States. From the new facility in Bristol, Pennsylvania, starting in October 2026, Telit Cinterion will serve the American and global markets with cellular 4G and 5G IoT modules, and OEM customer products such as routers and gateways.

The 8,000 square-foot facility will house manufacturing, testing, and quality assurance. Support functions including engineering and supply chain will be supported by the company’s existing offices in Research Triangle Park, North Carolina, and Boca Raton, Florida. The first phase of the initiative is expected to create at least 50 high-value jobs.

The start of U.S. production marks the first phase of Telit Cinterion’s long-term commitment to expanding domestic capabilities. The new operation establishes a foundation for continued investment in U.S. manufacturing, workforce development, and supply chain resiliency.

“The Bristol facility represents an important step in strengthening trusted technology supply chains and increasing domestic manufacturing capacity for IoT connected devices and AI-enabled solutions,” said Paolo Dal Pino, Telit Cinterion CEO. “It on shores our trusted manufacturing capability designed to provide U.S. and global customers with, greater traceability, quality assurance, operational resilience, and greater supply chain transparency that aligns with new regulations in the U.S. and western countries.”

More information about Telit Cinterion U.S. manufacturing may be found here.

About Telit Cinterion

Telit Cinterion is a global IoT leader with over 30 years of innovation experience. It provides modules, connectivity plans and services, platforms, and secure, scalable custom solutions.

Telit Cinterion’s product portfolio supports mission-critical applications across industries. In addition, it simplifies lifecycle management and device-to-cloud security. The company helps enterprises connect, manage and grow their IoT systems with confidence.

OEMs, system integrators and service providers worldwide trust Telit Cinterion. The company drives digital transformation and unlocks the power of connected technology.

For more information, follow us on YouTube, X, LinkedIn and Facebook. Visit telit.com or subscribe to receive our marketing communications.

Copyright © 2026 Telit IoT Solutions Holding Ltd. and/or its affiliated companies. All rights reserved. Telit Cinterion, Telit, OneEdge, Cinterion, and all associated logos are trademarks and/or registered trademarks of Telit Communications S.p.A, Telit Communications LTD, Telit IoT Solutions Holding Ltd. and/or their affiliated companies in the United States and/or other countries. Other names used herein may be trademarks of their respective owners.

Media Contacts

Greg Oppenheim
Telit Cinterion
+1 949-540-1278
Greg.Oppenheim@telit.com

Casey Bush
GRC for Telit Cinterion
telit@globalresultspr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/telit-cinterion-to-onshore-its-trusted-manufacturing-to-the-united-states-302868058.html

SOURCE Telit Cinterion